TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04588922: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Sponsor: Sellas Life Sciences Group · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 160 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,172,940

Rescue Site Savings

+$1,439,220

Unlock Full NCT04588922 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04588922 Rescue Dossier →